Browsing Tag
advanced melanoma
2 posts
Replimune Group (NASDAQ: REPL) plans layoffs after FDA rejects Tudriqev again, forcing a biotech reset
Replimune plans layoffs after the FDA rejected Tudriqev again. Read what the setback means for REPL stock, cash runway, strategy, and rivals.
April 11, 2026
Advanced melanoma immunotherapy enters a new phase as Scancell secures Phase 3 clearance
Scancell Holdings Plc, iSCIB1+, advanced melanoma, melanoma immunotherapy, FDA Phase 3 clearance, cancer vaccines, ImmunoBody platform
January 29, 2026